In summary, our study not only provides a potential strategy for cancer therapy by targeting the K70 site of ALDH1L2 but also suggests that the combination of SIRT3 inhibitor and 5-Fu may overcome 5-Fu resistance. This evidence concerns the gene ALDH1L2 and cancer.